Company Overview and News

142
Rounds Report: Ocular Rallied While Stellar FDA Due Diligence To Help Antibiotic Innovators

2018-06-13 seekingalpha
The overall bioscience market traded on an uptrend for the day. Many firms under our coverage continued to post further gains.
OCUL CDTX PRTK NVS IBB MLNT AKAO XBI RGEN

225
5 Clinical-Stage Biotech Stocks to Buy Under $10

2018-05-29 investorplace
Not many sectors offer the potential for big time gains like biotech. Especially when you’re looking at smaller clinical-stage names. After all, the thrill of getting a big-time approval or even making through to the next round of FDA trail phases can send a biotech stock’s price surging. Conversely, one mishap can send shares crashing.
OCUL AMGN GALTW JNJ ZFGN GALTU RARX VKTX GALT

40
EyePoint Pharmaceuticals' (EYPT) CEO Nancy Lurker on Q3 2018 Results - Earnings Call Transcript

2018-05-09 seekingalpha
Good day, ladies and gentlemen, and welcome to the Third Quarter Fiscal 2018 EyePoint Pharmaceuticals Earnings Conference Call. As a reminder, this conference call is being recorded.
OCUL SWKH EYPT

37
Ocular Therapeutix's (OCUL) CEO Antony Mattessich on Q1 2018 Results - Earnings Call Transcript

2018-05-08 seekingalpha
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Q1 2018 Results Earnings Conference Call May 8, 2018 4:30 PM ET
OCUL

40
OCUL / Ocular Therapeutix, Inc. 10-Q (Quarterly Report)

2018-05-08 sec.gov
ocul_Current_Folio_March 31, 2018 Table of Contents
OCUL

47
OCUL / Ocular Therapeutix, Inc. DEFA14A

2018-04-23 sec.gov
ocul_Current_Folio_DEFA14A
OCUL

45
OCUL / Ocular Therapeutix, Inc. DEF 14A

2018-04-23 sec.gov
ocul_Current_Folio_Proxy Table of Contents
OCUL

107
LogMeIn started at buy with $145 stock price target at Mizuho

2018-04-02 marketwatch
LogMeIn Inc. shares fell more than 5% in the extended session Thursday after the company missed revenue expectations and issued weaker-than-expected first-quarter guidance. The company reported fourth-quarter net income of $93.3 million, or $1.74 a share, compared with $1.9 million, or 7 cents a share, in the year-ago period. Adjusted earnings were $1.20 a share. Revenue rose to $279.9 million from $88 million in the year-ago period.
OCUL LOGM ALKS HALO EEFT PGRE MANH HDP POWI

84
pSivida's (PSDV) Management Discusses Acquisition of Icon Bioscience and Growth Capital Financing with Essex Woodlands Healthcare Partners Conference Call (Transcript)

2018-03-30 seekingalpha
pSivida Corp. (NASDAQ:PSDV) Acquisition of Icon Bioscience Inc and Growth Capital Financing with Essex Woodlands Healthcare Partners Conference Call March 29, 2018 8:00 AM ET
OCUL SWKH PSDV

53
Can the Rally in Ocular Therapeutix (OCUL) Shares Continue?

2018-03-22 zacks
Ocular Therapeutix, Inc. (OCUL - Free Report) has been on the move lately as the stock has risen by 38% in the past four weeks, and it is currently trading well above its 20-Day SMA. This is a pretty solid move higher, but the question that has to be on investors’ minds right now is; can this trend continue?
OCUL DUKH VSLR DUK TCKRF TECK

51
BioSci Rounds Report: Unlocking The Value Of Ocular Therapeutix And Updating Solid Bioscience

2018-03-20 seekingalpha
Ocular Therapeutics is starting to trade northbound as its market value is moving in the direction of its true worth.
OCUL REGN SLDB IBB XBI

62
5 ‘Strong Buy’ Biotechs That Can Double in 2018

2018-03-14 investorplace
According to top analysts on the Street, these five “Strong Buy” biotech stocks are primed for outsized growth in the next 12 months.
OCUL TGTX FLKS CLSD

OCUL : Ocular Therapeutix Stock Analysis and Research Report

2017-10-19 - Asif

Ocular Therapeutix is a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Its bioresorbable hydrogel-based drug product candidates are designed to provide extended delivery of therapeutic agents to the eye. Its lead product candidates are DEXTENZA (dexamethasone insert), for the treatment of post-surgical ocular inflammation and pain, allergic conjunctivitis and dry eye disease, and OTX-TP, for the treatment of glaucoma and ocular hypertension, which are extended-delivery, drug-eluting inserts that are placed into the canaliculus through a natural opening called the punctum located in the inner portion of the eyelid near the nose. Its intracanalicular inserts combine its hydrogel technology with U.S. Food and Drug Administration, or FDA, approved therapeutic agents with the goal of providing extended delivery of drug to the eye. Ocular also has...

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

Silicon Investor Message Boards

This table lists all message boards related to OCUL / Ocular Therapeutix, Inc. on message board site Silicon Investor.

Ocular Sciences (OCLR)
CUSIP: 67576A100